<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900055</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000823</org_study_id>
    <secondary_id>P01HL048546</secondary_id>
    <secondary_id>OHSU-HEM-98030-L</secondary_id>
    <nct_id>NCT00900055</nct_id>
  </id_info>
  <brief_title>Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma</brief_title>
  <official_title>Dysregulation of Hematopoiesis in Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with&#xD;
      Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory&#xD;
      may help doctors learn more about the causes of blood cancers.&#xD;
&#xD;
      PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow&#xD;
      cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders,&#xD;
      or myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify the specific molecular function of the Fanconi anemia (FA) complementing gene&#xD;
           products in hematopoietic progenitor cells from patients and normal volunteers.&#xD;
&#xD;
        -  Identify functional defects in hematopoietic stromal cells, including macrophages, from&#xD;
           patients with FA, and selected blood cancers as well as normal volunteers.&#xD;
&#xD;
      OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts&#xD;
      are collected for loss-of-function and gain-of-function analysis related to the Fanconi&#xD;
      anemia complementing gene.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 1975</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Loss of function analyses</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microsequencing of unique proteins</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of functional defects in Fanconi anemia hematopoietic stromal cells</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">213</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polyacrylamide gel electrophoresis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Center for Hematologic Malignancies, the Knight Cancer Institute at OHSU, and the Bone&#xD;
        Marrow Failure clinic at Doernbecher Children's Hospital at OHSU will be centers for&#xD;
        recruitment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of one of the following:&#xD;
&#xD;
                    -  Fanconi's anemia requiring bone marrow biopsy as part of standard care&#xD;
                       (adults and children)&#xD;
&#xD;
                    -  Myeloproliferative disorder or myeloma (adults)&#xD;
&#xD;
               -  Healthy volunteer, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Over 18 years of age&#xD;
&#xD;
                    -  Bone marrow transplant donor (children)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Hemoglobin &gt; 13 g/dL&#xD;
&#xD;
          -  White blood cells (WBC) &gt; 4,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 150,000/mm³&#xD;
&#xD;
          -  No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or&#xD;
             fungal)&#xD;
&#xD;
          -  No known blood abnormality (healthy volunteers)&#xD;
&#xD;
          -  No allergies to lidocaine or xylocaine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Newell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Laura Newell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Fanconi anemia</keyword>
  <keyword>multiple myeloma and other plasma cell neoplasms</keyword>
  <keyword>chronic myeloproliferative disorders</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

